Clinical aspects of modulation of glutamatergic mechanisms in the treatment of schizophrenia

Drugs of the Future

Volumn 35, Issue 7, 2010, Pages 557-566

  Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINOBUTYRIC ACID; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; LAMOTRIGINE; LOXAPINE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PIRACETAM; QUETIAPINE; RISPERIDONE; SARCOSINE;

ADD ON THERAPY; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DOWNSTREAM PROCESSING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GABAERGIC SYSTEM; HUMAN; INSOMNIA; MONOTHERAPY; MOUSE; NAUSEA; NEGATIVE SYNDROME; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; WEIGHT GAIN; XEROSTOMIA;

EID: 84952984503     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.07.1493930     Document Type: Review

References (152)

1. Lambert, M., Naber, D., Schacht, A. et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008, 118(3): 220-9.
2. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153(3): 321-30.
3. Meltzer, H.Y. Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 2002, 4(4): 279-83.
4. Carlsson, A., Waters, N., Carlsson, M.L. Neurotransmitter interactions in schizophrenia-Therapeutic implications. Biol Psychiatry 1999, 46(10): 1388-95.
5. Castner, S.A., Goldman-Rakic, P.S., Williams, G.V. Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 2004, 174(1): 111-25.
6. Gold, J.M., Weinberger, D.R. Cognitive deficits and the neurobiology of schizophrenia. Curr Opin Neurobiol 1995, 5(2): 225-30.
7. Meltzer, H.Y., McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25(2): 233-55.
8. Miyamoto, S., Duncan, C.E., Marx, C.E., Lieberman, J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10(1): 79-104.
9. Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry Suppl 1999, (38): 44-51.
10. Erhart, S.M., Marder, S.R., Carpenter, W.T. Treatment of schizophrenia negative symptoms: Future prospects. Schizophr Bull 2006, 32(2): 234-7.
11. Kirkpatrick, B., Buchanan, R.W., Ross, D.E., Carpenter, W.T. Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001, 58(2): 165-71.
12. Kirkpatrick, B., Fenton, W.S., Carpenter, W.J. Jr., Marder, S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32(2): 214-9.
13. Carpenter, W.T. Jr., Heinrichs, D.W., Alphs, L.D. Treatment of negative symptoms. Schizophr Bull 1985, 11(3): 440-52.
14. Hummer, M., Huber, J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004, 20(2): 189-97.
15. Llorca, P.M., Chereau, I., Bayle, F.J., Lancon, C. Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 2002, 17(3): 129-38.
16. Sathyaprakash, R., Henry R.R. Hyperglycemia with antipsychotic treatment. Curr Diab Rep 2004, 4(1): 41-5.
17. Schwartz, T.L., Nihalani, N., Virk, S., Jindal, S., Chilton, M. Psychiatric medication-induced obesity: Treatment options. Obes Rev 2004, 5(4): 233-8.
18. Ascher-Svanum, H., Faries, D.E., Zhu, B., Ernst, F.R., Swartz, M.S., Swanson, J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67(3): 453-60.
19. Ayuso-Gutiérrez, J.L., del Río Vega, J.M. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997, 28(2-3): 199-206.
20. Morken, G., Widen, J.H., Grawe, R.W. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8: 32.
21. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264(19): 2511-8.
22. Davis, K.L., Buchsbaum, M.S., Shihabuddin, L., Spiegel-Cohen, J., Metzger, M., Frecska, E., Keefe, R.S., Powchik, P. Ventricular enlargement in poor-outcome schizophrenia. Biol Psychiatry 1998, 43(11): 783-93.
23. DeLisi, L.E., Tew, W., Xie, S. et al. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: Preliminary findings. Biol Psychiatry 1995, 38(6): 349-60.
24. Gur, R.E., Cowell, P., Turetsky, B.I., Gallacher, F., Cannon, T., Bilker, W., Gur, R.C. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998, 55(2): 145-52.
25. Jarskog, L.F., Glantz, L.A., Gilmore, J.H., Lieberman, J.A. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(5): 846-58.
26. Carlsson, A., Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963, 20: 140-4.
27. Weinberger, D.R. Schizophrenia drug says goodbye to dopamine. Nat Med 2007, 13(9): 1018-9.
28. Bleich, S., Römer, K., Wiltfang, J., Kornhuber, J. automate and the glutamate receptor system: A target for drug action. Int J Geriatr Psychiatry 2003, 18(Suppl. 1): S33-40.
29. Stone, J.M. Imaging the glutamate system in humans: Relevance to drug discovery for schizophrenia. Curr Pharm Des 2009, 15(22): 2594-602.
30. Allen, R.M., Young, S.J. Phencyclidine-induced psychosis. Am J Psychiatry 1978, 135(9): 1081-4.
31. Javitt, D.C., Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148(10): 1301-8,
32. Luby, E.D., Cohen, B.D., Rosenbaum, G., Gottlieb, J.S., Kelley, R. Study of a new schizophrenomimetic drug; Sernyl. AMA Arch Neurol Psychiatry 1959, 81(3): 363-9.
33. Luby, E.D. Phencyclidine revisited. In: PCP (Phencyclidine): Historical and Current Perspectives. E.F. Domino (Ed.). NPP Books: Ann Arbor, Michigan, 1981, 25-30.
34. Javitt, D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987, 9(1): 12-35.
35. Anis, N.A., Berry, S.C., Burton, N.R., Lodge, D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983, 79(2): 565-75.
36. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W., Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20(3): 379-82.
37. Olney, J.W., Farber, N B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52(12): 998-1007.
38. Zukin, S.R., Zukin, R.S. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979, 76(10): 5372-6.
39. Callicott, J.H., Mattay, V.S., Verchinski, B.A., Marenco, S., Egan, M.F., Weinberger, D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: More than up or down. Am J Psychiatry 2003, 160(12): 2209-15.
40. Cannon, T.D., Glahn, D.C., Kim, J. et al. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch Gen Psychiatry 2005, 62(10): 1071-80.
41. MacDonald, A.W. 3rd, Carter, C.S., Kerns, J.G. et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry 2005, 162(3): 475-84.
42. Tan, H.Y., Choo, W.C., Fones, C.S., Chee, M.W. fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. Am J Psychiatry 2005, 162(10): 1849-58.
43. Williams, G.V., Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376(6541): 572-5.
44. Winterer, C., Weinberger, D.R. Genes, dopamine and conical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004, 27(11): 683-90.
45. Goldman-Rakic, P.S. Cellular basis of working memory. Neuron 1995, 14(3): 477-85.
46. Goldman-Rakic, P.S. The "psychic" neuron of the cerebral cortex. Ann NY Acad Sci 1999, 868: 13-26.
47. Durstewitz, D., Seamans, J.K. Beyond bistability: Biophysics and temporal dynamics of working memory. Neuroscience 2006, 139(1): 119-33.
48. Kawaguchi, Y. Distinct firing patterns of neuronal subtypes in cortical synchronized activities. J Neurosci 2001, 21(18): 7261-72.
49. Lewis, D.A., Gonzélez-Burgos, G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33(1): 141-65.
50. Lewis, D.A., Hashimoto, T., Volk, D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6(4): 312-24.
51. Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, C., Wu, C. Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 2004, 5(10): 793-807.
52. Wang, X.J. Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia. Pharmacopsychiatry 2006, 39(Suppl. 1): S80-7.
53. Homayoun, H., Moghaddam, B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27(43): 11496-500.
54. Homayoun, H., Moghaddam, B. Fine-tuning of awake prefrontal cortex neurons by clozapine: Comparison with haloperidol and N-desmethyl-clozapine. Biol Psychiatry 2007, 61(5): 679-87.
55. Adler, C.M., Goldberg, T.E., Malhotra, A.K., Pickar, D., Breier, A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998, 43(11): 811-6.
56. Krystal, J.H., Karper, L.P., Seibyl, J.P. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51(3): 199-214.
57. Newcomer, J.W., Farber, N.B., Jevtovic-Todorovic, V. et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20(2): 106-18.
58. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., Angst, J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997, 7(1): 9-24. (Pubitemid 27139716)
59. Vollenweider, F.X., Geyer, M.A. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 2001, 56(5): 495-507.
60. Cosgrove, J., Newell, T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 1991, 47(1): 159-69.
61. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13(1): 9-19.
62. Javitt, D.C., Balla, A., Burch, S., Suckow, R., Xie, S., Sershen, H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004, 29(2): 300-7.
63. Breier, A., Malhotra, A.K., Pinals, D.A., Weisenfeld, N.I., Pickar, D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997, 154(6): 805-11.
64. Lahti, A.C., Holcomb, H.H., Medoff, D.R., Tamminga, C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6(6): 869-72.
65. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., Breier, A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17(3): 141-50.
66. Duncan, G.E., Moy, S.S., Knapp, D.J., Mueller, R.A., Breese, G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia. Brain Res 1998, 787(2): 181-90.
67. Weissman A.D., Dam M., London E.D. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 1987, 435(1-2): 29-40. (Pubitemid 18009769)
68. Farber, N.B., Price, M.T., Labruyere, J., Nemnich, J., St. Peter, H., Wozniak, D.F., Olney, J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993, 34(1-2): 119-21.
69. Lieberman, J.A., Bymaster, F.P., Meltzer, H.Y. et al. Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008, 60(3): 358-403.
70. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 2001, 156(2-3): 117-54.
71. Javitt, D.C., Lindsley, R.W. Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology (Berl) 2001, 156(2-3): 165-8.
72. Linn, C.S., Negi, S.S., Gerum, S.V., Javitt, D.C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 2003, 169(3-4): 234-9.
73. van Berckel, B.N., Oranje, B., van Ree, J.M., Verbaten, M.N., Kahn, R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 1998, 137(3): 271-81.
74. Duncan, E.J., Madonick, S.H., Parwani, A. et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 2001, 25(1): 72-83.
75. Abel, K.M., Allin, M.P., Hemsley, D.R., Geyer, M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 2003, 44(6): 729-37.
76. Heresco-Levy, U., Bar, G., Levin, R., Ermilov, M., Ebstein, R.P., Javitt, D.C. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res 2007, 91(1-3): 14-21.
77. Mohn, A.R., Gainetdinov, R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98(4): 427-36.
78. Akbarian, S., Sucher, N.J., Bradley, D. et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996, 16(1): 19-30.
79. Clinton, S.M., Meador-Woodruff, J.H. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004, 29(7): 1353-62.
80. Grimwood, S., Slater, P., Deakin, J.F., Hutson, P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999, 10(3): 461-5.
81. Humphries, C., Mortimer, A., Hirsch, S., de Belleroche, J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 1996, 7(12): 2051-5.
82. Ishimaru, M., Kurumaji, A., Toru, M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis. Biol Psychiatry 1994, 35(2): 84-95.
83. Pilowsky, L.S., Bressan, R.A., Stone, J.M., Erlandsson, K., Mulligan, R.S., Krystal, J.H., Ell, P.J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006, 11(2): 118-9.
84. Simpson, M.D., Slater, P., Royston, M.C., Deakin, J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 1991, 6(1): 41-8.
85. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71(4): 877-92.
86. Tsai, G., Passani, L.A., Slusher, B.S., Carter, R., Baer, L., Kleinman, J.E., Coyle, J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995, 52(10): 829-36.
87. Bodor, A.L., Katona, I., Nyíri, G., Mackle, K., Ledent, C., Hájos, N., Freund, T.F. Endocannabinoid signaling in rat somatosensory cortex: Laminar differences and involvement of specific interneuron types. J Neurosci 2005, 25(29): 6845-56.
88. Eggan, S.M., Lewis, D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: A regional and laminar analysis. Cereb Cortex 2007, 17(1): 175-91.
89. Katona, I., Sperlágh, B., Sík, A., Käfalvi, A., Vizi, E.S., Mackie, K., Freund, T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999, 19(11): 4544-58.
90. Fergusson, D.M., Poulton, R., Smith, P.F., Boden, J.M. Cannabis and psychosis. BMJ 2006, 332(7534): 172-5.
91. Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H. Clozapine in treatmentresistant schizophrenics. Psychopharmacol Bull 1988, 24(1): 62-7.
92. McEvoy, J.P., Lieberman, J.A., Stroup, T.S. et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163(4): 600-10.
93. Malhotra, A.K., Adler, C.M., Kennison, S.D., Elman, I., Pickar, D., Breier, A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 1997, 42(8): 664-8.
94. Okuyama, S., Chaki, S., Kawashima, N. et al. The atypical antipsychotic profile of NRA0045, a novel dopamine DA and 5-hydroxytryptamine2A receptor antagonist, in rats. Br J Pharmacol 1997, 121(3): 515-25.
95. Bakshi, V.P., Swerdlow, N.R., Geyer, M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994, 271(2): 787-94.
96. Keith, V. A., Mansbach, R.S., Geyer, M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991, 30(6): 557-66.
97. Swerdlow, N.R., Bakshi, V., Geyer, M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996, 279(3): 1290-9.
98. Wang, R.Y., Liang, X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 1998, 19(1): 74-85.
99. Ninan, I., Jardemark, K.E., Wang, R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 2003, 48(2): 66-79. (Pubitemid 36374000)
100. Daly, D.A., Moghaddam, B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993, 152(1-2): 61-4.
101. Karoum, F., Egan, M.F. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: A comparison of acute clozapine and haloperidol. Br J Pharmacol 1992, 105(3): 703-7.
102. Kuroki, T., Meltzer, H.Y., Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999, 288(2): 774-81.
103. Moghaddam, B., Bunney, B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990, 54(5): 1755-60.
104. Ninan, I., Wang, R.Y. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: Pharmacological evidence. Eur J Neurosci 2006, 17(6): 1306-12.
105. Yamamoto, B.K., Pehek, E.A., Meltzer, H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 1994, 55(Suppl. B): 8-14.
106. Youngren, K.D., Moghaddam, B., Bunney, B.S., Roth, R.H. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 1994, 165(1-2): 41-4.
107. Youngren, K.D., Inglis, F.M., Pivirotto, P.J. et al. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 1999, 20(5): 403-12.
108. Ossowska, K., Pietraszek, M., Wardas, J., Nowak, G., Wolfarth, S. Influence of long-lasting administration of neuroleptics on cortical NMDA receptors and phencyclidine-induced deficit in the sensorimotor gating in rats. Pol J Pharmacol 1999, 51(1): 49-53.
109. Johnson, J.W., Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325(6104): 529-31.
110. Kleckner, N.W., Dingledine, R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988, 241(4867): 835-7.
111. Javitt, D.C., Balla, A., Sershen, H., Lajtha, A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 1999, 45(6): 668-79.
112. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9(11): 984-97, 979.
113. Nilsson, M., Carlsson, A., Carlsson, M.L. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 1997, 104(11-12): 1195-205.
114. Heresco-Levy, U., Javitt, D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis. Schizophr Res 2004, 66(2-3): 89-96.
115. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Horowitz, A., Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996, 169(5): 610-7.
116. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56(1): 29-36.
117. Cascella, N.G., Macclardi, F., Cavallini, C., Smeraldi, E. d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transm Gen Sect 1994, 95(2): 105-11.
118. Goff, D.C., Tsai, C., Manoach, D.S., Coyle, J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995, 152(8): 1213-5.
119. Goff, D.C., Tsai, G., Manoach, D.S., Flood, J., Darby, D.G., Coyle, J.T. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996, 153(12): 1628-30.
120. Goff, D.C., Tsai, G., Levitt, J. et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999, 56(1): 21-7.
121. van Berckel, B.N., Hijman, R., van der Linden, J.A., Westenberg, H.G., van Ree, J.M., Kahn, R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996, 40(12): 1298-300.
122. Rosse, R.B., Fay-McCarthy, M., Kendrick, K., Davis, R.E., Deutsch, S.I. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 1996, 19(5): 444-50.
123. Tuominen, H.J., Tiihonen, J., Wahlbeck, K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 2005, 72(2-3): 225-34.
124. Buchanan, R.W., Javitt, D.C., Marder, S.R. et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164(10): 1593-602.
125. Javitt, D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008, 63(1): 6-8.
126. Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C., Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005, 62(11): 1196-204.
127. Tsai, G., Lane, H.Y., Yang, P., Chong, M.Y., Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004, 55(5): 452-6.
128. Lane, H.Y., Liu, Y.C., Huang, C.L., Chang, Y.C., Liau, C.H., Perng, C.H., Tsai, C.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008, 63(1): 9-12.
129. Rogers, B.N., Schmidt, C.J. Novel approaches for the treatment of schizophrenia. In: Annual Reports in Medicinal Chemistry, Vol. 41. A. Wood (Ed.). Elsevier Inc.: London, 2006, 3-21.
130. Malinow, R., Malenka, R.C. AMRA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002, 25: 103-26.
131. Meador-Woodruff, J.H., Healy, D.J. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000, 31(2-3): 288-94.
132. Hampson, R.E., Rogers, G., Lynch, G., Deadwyler, S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: Correlations with hippocampal neuronal activity. J Neurosci 1998, 18(7): 2748-63.
133. Staubli, U., Rogers, G., Lynch, G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 1994, 91(2): 777-81.
134. Noorbala, A.A., Akhondzadeh, S., Davari-Ashtiani, R., Amini-Nooshabadi, H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 1999, 24(5): 369-74.
135. Goff, D.C., Leahy, L., Berman, I. et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001, 21(5): 484-7.
136. Goff, D.C., Lamberti, J.S., Leon, A.C. et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33(3): 465-72.
137. Xie, X., Lancaster, B., Peakman, T., Garthwaite, J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch 1995, 430(3): 437-46.
138. Brody, S.A., Geyer, M.A., Large, C.H. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 2003, 169(3-4): 240-6.
139. Ong, J.C., Brody, S.A., Large, C.H., Geyer, M.A. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 2005, 315(3): 1163-71.
140. Anand, A., Charney, D.S., Oren, D.A., Berman, R.M., Hu, X.S., Cappiello, A., Krystal, J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000, 57(3): 270-6.
141. Large, C.H., Webster, E.L., Goff, D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 2005, 181(3): 415-36.
142. Goff, D.C., Keefe, R., Citrome, L. et al. Lamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007, 27(6): 582-9.
143. Liu, F., Zhang, G., Hornby, G. et al. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur J Pharmacol 2006, 536(3): 262-8.
144. Lecourtier, L., Homayoun, H., Tamagnan, G., Moghaddam, B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007, 62(7): 739-46.
145. Liu, F., Grauer, S., Kelley, C. et al. ADX47273 [S-(4-fluoro-phenyl)-{3- [3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and pro-cognitive activities. J Pharmacol Exp Ther 2008, 327(3): 827-39.
146. Gaspar, P.A., Bustamante, M.L., Silva, H., Aboitiz, F. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: Therapeutic implications. J Neurochem 2009, 111(4): 891-900.
147. Patil S.T., Zhang L., Martenyi F. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007, 13(9): 1102-7.
148. Kinon, B.J., Zhang, L., McKinzie, D., Martenyi, F., Breier, A. mGlu2/3 receptor agonists: A non-dopamine treatment approach for schizophrenia. 6th Int Meet Metabotropic Glutamate Receptors (Sept 14-19, Taormina) 2008.
149. Kinon, B.J. LY2140023-CLIN: LY2140023 monohydrate: An agonist at the mGlu2/3 receptor for the treatment of schizophrenia. Int Congr Schizophr Res (March 26-28, San Diego,) 2009.
150. Fell, M.J., Svensson, K.A., Johnson, B.G., Schoepp, D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326(1): 209-17.
151. Ghose, S., Gleason, K.A., Potts, B.W., Lewis-Amezcua, K., Tamminga, C.A. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action? Am J Psychiatry 2009, 166(7): 812-20.
152. Long, K.D., Mastropaolo, J., Rosse, R.B., Manaye, K.F., Deutsch, S.I. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically bred BALB/c mouse strain. Brain Res Bull 2006, 69(6): 626-30.